Earnings Per Share, Diluted of Maze Therapeutics, Inc. from 31 Mar 2024 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD/shares
- Description
- The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
- Summary
-
Maze Therapeutics, Inc. quarterly and annual Earnings Per Share, Diluted in USD/shares history and change rate from 31 Mar 2024 to 31 Dec 2025.
- Maze Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending 31 Dec 2025 was -0.47, a 102% decline year-over-year.
- Maze Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending 31 Dec 2025 was -3.05, a 344% decline year-over-year.
- Maze Therapeutics, Inc. annual Earnings Per Share, Diluted for 2025 was -3.05, a 344% decline from 2024.
- Source SEC data
- View on sec.gov
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Change (%)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Change (%)
Maze Therapeutics, Inc. Quarterly Earnings Per Share, Diluted (USD/shares)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -3.05 | -0.47 | -22.66 | -102% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| Q3 2025 | 19.61 | -0.66 | +9.59 | +94% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 06 Nov 2025 | 2025 | Q3 |
| Q2 2025 | 10.02 | -0.77 | -3.99 | -124% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q2 |
| Q1 2025 | 14.01 | -1.15 | +12.76 | +92% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q1 |
| Q4 2024 | 1.25 | 22.19 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY | ||
| Q3 2024 | -10.25 | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 06 Nov 2025 | 2025 | Q3 | |||
| Q2 2024 | 3.22 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q2 | |||
| Q1 2024 | -13.91 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 14 May 2025 | 2025 | Q1 |
Maze Therapeutics, Inc. Annual Earnings Per Share, Diluted (USD/shares)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | -3.05 | -4.3 | -344% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| 2024 | 1.25 | 01 Jan 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.